Principal Statistician

Responsibilities

• Work directly in clinical trial datasets to identify efficacy signals, safety patterns, and subgroup effects that inform pipeline decisions
• Build rigorous statistical analyses from scratch including mixed-effects models, longitudinal models, Bayesian frameworks, and sensitivity analyses
• Monitor emerging safety signals across ongoing studies and contextualize findings for leadership
• Pressure-test clinical assumptions, challenge endpoint choices, and scrutinize statistical analysis plans
• Execute focused analytical sprints on high-priority questions from leadership
• Develop deep reads of clinical evidence bases and analyze competitors' trial data with equal rigor
• Synthesize findings from literature, registries, claims, and proprietary datasets into coherent narratives
• Drive selection and integration of data sources and help build shared analytical infrastructure across Roivant and Vant companies

Requirements

• Exceptional academic background in statistics, mathematics, computer science, or a related quantitative field
• Deep command of statistical and computational methods including mixed-effects models, longitudinal analyses, Bayesian approaches, and machine learning
• Demonstrated interest in life sciences, biology, or health
• Hands-on experience building analyses from scratch with large, complex datasets
• Track record of translating rigorous analysis into actionable decisions
• Ability to communicate complex quantitative findings clearly to non-technical and CEO-level audiences
• High capacity for learning and comfort operating in ambiguous domains

Benefits

• Meaningful equity participation
• Comprehensive company-sponsored benefits package
• Expected base salary range of $130,000 to $220,000 per year

About the Company

Roivant Sciences was founded in 2014 to improve health by rapidly delivering innovative medicines and technologies to patients. The company employs a decentralized model of focused companies ("Vants") centered on drug development and technology innovation, with five approved medicines and multiple public biotechs created from its platform. Roivant is preparing to become a breakout commercial-stage biotech with the launches of brepocitinib, IMVT-1402, and mosliciguat.